Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 14/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239156 | 0.85 | TSHR (0.55) | PARP1TSHRHTTRIPK1ALOX5 | |
| SCHEMBL4246220 | 0.85 | PARP1 (0.48) | PARP1PARP2RAD52UHRF1 | |
| SCHEMBL5333943 | 0.82 | PARP1 (0.56) | PARP1PARP2 | |
| SCHEMBL4078709 | 0.80 | RIPK1 (0.58) | PARP1TSHRHTTRIPK1ALOX5 | |
| SCHEMBL4246128 | 0.80 | PDE10A (0.51) | PARP1PARP2RAD52UHRF1 | |
| SCHEMBL4243732 | 0.79 | HTT (0.56) | PARP1TSHRHTTPARP2 | |
| SCHEMBL2927811 | 0.78 | RIPK1 (0.62) | TSHRHTTRIPK1ALOX5DRD2 | |
| SCHEMBL4243580 | 0.78 | PARP1 (0.62) | PARP1PARP2 | |
| SCHEMBL1933246 | 0.77 | PARP1 (0.69) | PARP1PARP2 | |
| SCHEMBL8967020 | 0.77 | RIPK1 (0.50) | PARP1TSHRHTTRIPK1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946259-B2 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-03-06 | — | — | US | disclosed |
| US-8598353-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2457901-A1 | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors | High Point Pharmaceuticals, LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | VTVX HOLDINGS II LLC | 2009-12-31 | — | — | US | disclosed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | PARP1 1741/4885TSHR 4866/4885HTT 472/4885 |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | BACE1, BACE2, APP | PARP1 1741/4885TSHR 4866/4885HTT 472/4885 |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | PARP1 1741/4885TSHR 4866/4885HTT 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.